BiomX (PHGE)
:PHGE
Want to see PHGE full AI Analyst Report?
Top Page
BiomX
(PHGE)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.69
▼(-62.45% Downside)
Action:Reiterated
Date:06/02/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and continued cash burn alongside negative equity). Technicals also remain unfavorable with the stock far below key moving averages and negative MACD. Corporate events provide some offset via the strategic shift into defense/security and early contract progress, but delisting/compliance and funding risks limit the net benefit, while valuation signals are weak due to negative earnings and no dividend.
Positive Factors
Acquisition adds production‑grade revenue and defense customers
Acquiring ZorroNet brings an operational, revenue‑generating business with validated deployments for major defense and infrastructure customers. This materially reduces commercialization risk versus a pure R&D biotech profile and provides a durable revenue base and reference clients for scaling sales in defense markets.
Negative Factors
Persistent cash burn and negative equity
The company remains pre‑revenue in key historic segments and continues to consume significant cash with negative operating and free cash flow. Negative stockholders' equity signals balance‑sheet strain, reducing financial flexibility and forcing reliance on external financing to sustain operations and pursue acquisitions.
Read all positive and negative factors
Positive Factors
Negative Factors
Acquisition adds production‑grade revenue and defense customers
Acquiring ZorroNet brings an operational, revenue‑generating business with validated deployments for major defense and infrastructure customers. This materially reduces commercialization risk versus a pure R&D biotech profile and provides a durable revenue base and reference clients for scaling sales in defense markets.
Read all positive factors
BiomX (PHGE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.51M
Dividend YieldN/A
Average Volume (3M)1.32M
Price to Earnings (P/E)―
Beta (1Y)0.02
Revenue GrowthN/A
EPS Growth-92.20%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-23.30
Shares Outstanding10,146,516
10 Day Avg. Volume1,108,900
30 Day Avg. Volume1,322,820
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-100.26
Price to Sales (P/S)0.00
P/FCF Ratio-4.95
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.31
Enterprise Value/Ebitda-0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-12.24
Revenue Forecast (FY)N/A
BiomX Business Overview & Revenue Model
Company Description
BiomX Inc., a holding company, focuses on defense, security, and critical infrastructure technologies. The company's portfolio targets various niches, such as counter-drone systems, AI-enabled command-and-control, perimeter and border security, wi...
How the Company Makes Money
BiomX is a clinical-stage biotech and, to the extent publicly described for such companies, it does not primarily generate recurring product revenue because its therapeutic candidates are in development and not yet broadly commercialized. As a res...
BiomX Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 13, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in clinical trials and positive regulatory feedback which provides a strong outlook for future developments. However, financial challenges and regulatory holds present ongoing risks. Optimism in phage therapy's future and strategic plans for BX011 and BX004 suggest a cautiously positive sentiment.Positive Updates
BX004 Phase IIb Trial Progress and FDA Feedback
The BX004 program for cystic fibrosis patients showed significant progress with first patient dosing in the Phase IIb trial. Despite a clinical hold on U.S. trial sites due to a third-party nebulizer device, the European trial continues uninterrupted. FDA feedback recognized the unmet need for treatments targeting chronic Pseudomonas aeruginosa infections and provided constructive guidance for development pathways, including Phase III criteria.
Negative Updates
Clinical Hold on BX004 U.S. Trial Sites
The FDA placed a clinical hold on BX004 U.S. trial sites due to concerns with a third-party nebulizer device, not the drug candidate itself. This temporary pause affects U.S. sites while awaiting further FDA feedback, although European enrollment continues as planned.
Read all updates
Q3-2025 Updates
Positive
Negative
BX004 Phase IIb Trial Progress and FDA Feedback
The BX004 program for cystic fibrosis patients showed significant progress with first patient dosing in the Phase IIb trial. Despite a clinical hold on U.S. trial sites due to a third-party nebulizer device, the European trial continues uninterrupted. FDA feedback recognized the unmet need for treatments targeting chronic Pseudomonas aeruginosa infections and provided constructive guidance for development pathways, including Phase III criteria.
Read all positive updates
Company Guidance
During the BiomX Third Quarter 2025 Financial Results and Program Update Conference Call, the company provided guidance on several metrics. BiomX reported a cash balance of $8.1 million as of September 30, 2025, with expectations that this would fund operations into the first quarter of 2026. Research and development expenses decreased to $6.1 million from $7.3 million in the same quarter of 2024, largely due to workforce reductions and lower rent expenses. The company also noted a net loss of $9.2 million for the quarter, compared to a net income of $9.6 million the previous year, primarily due to changes in the fair value of warrants from its March 2024 financing. Additionally, BiomX is advancing its lead programs, BX004 and BX011, with regulatory engagement and clinical trial progress, despite a temporary FDA clinical hold on BX004 due to a third-party nebulizer device. They expect to report BX004 Phase IIb data in Q1 2026 and have received positive FDA feedback for BX011's development pathway.BiomX Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.69M | -2.92M | -1.80M | -871.00K | 0.00 | 0.00 |
| EBITDA | -44.54M | -29.99M | -13.13M | -22.82M | -23.66M | -32.90M |
| Net Income | -47.68M | -36.20M | -17.73M | -26.17M | -28.32M | -36.23M |
Balance Sheet | ||||||
| Total Assets | 3.25M | 70.24M | 43.23M | 25.03M | 45.53M | 77.99M |
| Cash, Cash Equivalents and Short-Term Investments | 1.17M | 4.96M | 17.81M | 14.91M | 33.33M | 62.10M |
| Total Debt | 0.00 | 1.44M | 9.58M | 15.09M | 19.36M | 20.02M |
| Total Liabilities | 4.13M | 71.54M | 19.09M | 21.95M | 24.49M | 30.45M |
| Stockholders Equity | -881.00K | -1.30M | 24.15M | 3.08M | 21.04M | 47.53M |
Cash Flow | ||||||
| Free Cash Flow | -23.09M | -26.39M | -37.01M | -21.34M | -29.20M | -31.25M |
| Operating Cash Flow | -23.09M | -26.39M | -36.98M | -21.29M | -29.09M | -27.57M |
| Investing Cash Flow | -939.00K | 108.00K | 715.00K | 1.95M | -2.11M | 16.17M |
| Financing Cash Flow | 3.90M | 13.19M | 38.37M | 2.90M | 292.00K | 37.28M |
BiomX Technical Analysis
Negative
1.84
Price Trends
1.61
Negative
3.35
Negative
5.34
Negative
Market Momentum
-0.16
Negative
39.20
Neutral
13.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHGE, the sentiment is Negative. The current price of 1.84 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 1.61, and below the 200-day MA of 5.34, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 39.20 is Neutral, neither overbought nor oversold. The STOCH value of 13.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHGE.
BiomX Risk Analysis
BiomX disclosed 72 risk factors in its most recent earnings report. BiomX reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BiomX Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $18.22M | -1.22 | -66.69% | ― | -45.52% | -94.82% | |
44 Neutral | $9.68M | -2.48 | -49.00% | ― | 11.90% | 43.46% | |
42 Neutral | $8.51M | -0.04 | -154.50% | ― | ― | -92.20% | |
41 Neutral | $6.61M | -778.30 | ― | ― | ― | ― |
* Healthcare Sector Average
PHGE
BiomX
0.72
-8.19
-91.92%
CANF
Can-Fite BioPharma
3.09
-18.81
-85.89%
LPCN
Lipocine
2.05
-1.12
-35.33%
IMRN
Immuron
1.25
-0.45
-26.47%
OSRH
OSR Holdings
0.39
-0.97
-71.47%
BiomX Corporate Events
M&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
BiomX Issues Restricted Shares Under Mandragola Credit Facility
Neutral
Jun 5, 2026
On June 2, 2026, BiomX Inc. issued 1,013,637 restricted common shares to three assignees upon partial conversion of a Mandragola Ltd. convertible promissory note, reflecting about $379,000 in principal, and bringing total shares outstanding to 11,...
Business Operations and StrategyExecutive/Board Changes
BiomX Appoints Roy Rousso as Chief Business Officer
Positive
May 28, 2026
On May 27, 2026, BiomX Inc. announced that its board appointed Colonel (res.) Roy Rousso as Chief Business Officer, effective July 1, 2026, bringing more than 20 years of leadership experience in digital infrastructure, sovereign cloud, private ce...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesLegal ProceedingsRegulatory Filings and Compliance
BiomX Reinvents Itself as Diversified Defense Technology Platform
Negative
May 5, 2026
In the first quarter of 2026, BiomX completed a fundamental strategic overhaul, halting all clinical trials, winding down its U.S. phage unit and exiting its legacy biotech operations after its former core subsidiary, BiomX Ltd., entered insolvenc...
Business Operations and Strategy
BiomX Subsidiary Zorronet Secures Israel Railways Supply Deal
Positive
Apr 16, 2026
On April 15, 2026, BiomX subsidiary Zorronet signed a 12‑month framework supply agreement with state-owned Israel Railways after a year-long pilot that cost Israel Railways about NIS 800,000 and delivered a 98% success rate in keeping large ...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
BiomX Acquires Majority Stake in DFSL Security Subsidiary
Positive
Apr 13, 2026
On April 13, 2026, BiomX exercised an exclusive option and closed a Stock Purchase Assignment Agreement with Mandragola Ltd. to acquire 100% of Mandragola’s holdings in DR. Frucht Systems Ltd., giving BiomX control of 60% of DFSL’s eq...
Business Operations and StrategyShareholder Meetings
BiomX Stockholders Approve 2026 Equity Incentive Plan
Positive
Apr 10, 2026
On April 10, 2026, BiomX Inc. held a special meeting of stockholders at which holders of 3,409,604 votes out of 6,543,516 outstanding common shares were present in person or by proxy, representing a majority of the company’s voting power. St...
Business Operations and StrategyM&A Transactions
BiomX Closes ZorroNet Acquisition, Enters AI Defense Sector
Positive
Apr 10, 2026
On April 10, 2026, BiomX Inc. closed the acquisition of Israeli AI defense technology firm ZorroNet from Water IO, issuing 1.3 million shares and a $1.25 million non-convertible note due July 7, 2026 as consideration. The deal also includes a perf...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
BiomX Secures Option to Acquire Defense Tech Company
Positive
Apr 1, 2026
On March 31, 2026, BiomX Inc. entered into an Option and Undertaking Agreement with Mandragola Ltd. granting BiomX an exclusive, irrevocable option to acquire Mandragola’s full shareholding in DR. Frucht Systems Ltd., contingent on Mandragol...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
BiomX Receives NYSE American Noncompliance Delisting Notice
Negative
Mar 27, 2026
On March 25, 2026, BiomX received a notice from NYSE American stating it was not in compliance with multiple continued listing standards because its stockholders’ equity fell below required minimums after several years of net losses. The com...
Business Operations and StrategyPrivate Placements and Financing
BiomX Details Financial Stabilization and Strategic Repositioning Plans
Positive
Mar 19, 2026
On March 13, 2026, BiomX amended a warrant originally issued in connection with a December 26, 2025 investment, cutting its term from five years to an expiration date of December 31, 2026 and halving the exercise price from $2.00 to $1.00 per shar...
Private Placements and FinancingShareholder Meetings
BiomX Shareholders Approve Expanded Common Stock Issuance Authorization
Positive
Mar 12, 2026
On March 11, 2026, BiomX Inc. held a special meeting of stockholders, reconvened after adjournment from February 25, 2026, at which all 1,593,516 outstanding common shares were represented and voted with no broker non-votes recorded. Shareholders ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.